382 related articles for article (PubMed ID: 11085345)
1. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Paul R; Breul J
Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
[TBL] [Abstract][Full Text] [Related]
2. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
4. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Small EJ; Srinivas S
Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
6. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
Small EJ; Vogelzang NJ
J Clin Oncol; 1997 Jan; 15(1):382-8. PubMed ID: 8996165
[TBL] [Abstract][Full Text] [Related]
7. The antiandrogen withdrawal syndrome.
Wirth MP; Froschermaier SE
Urol Res; 1997; 25 Suppl 2():S67-71. PubMed ID: 9144890
[TBL] [Abstract][Full Text] [Related]
8. Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.
Noguchi K; Teranishi J; Uemura H; Fujikawa N; Saito K; Murai T
Int J Urol; 2006 Sep; 13(9):1259-61. PubMed ID: 16984567
[TBL] [Abstract][Full Text] [Related]
9. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
[TBL] [Abstract][Full Text] [Related]
10. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Akakura K; Akimoto S; Furuya Y; Ito H
Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.
Leone G; Tucci M; Buttigliero C; Zichi C; Pignataro D; Bironzo P; Vignani F; Scagliotti GV; Di Maio M
Endocr Relat Cancer; 2018 Jan; 25(1):R1-R9. PubMed ID: 28971898
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Small EJ; Baron A; Bok R
Cancer; 1997 Nov; 80(9):1755-9. PubMed ID: 9351544
[TBL] [Abstract][Full Text] [Related]
13. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
El-Gabry EA; Strup SE; Gomella LG
Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
16. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher HI; Kelly WK
J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
[TBL] [Abstract][Full Text] [Related]
17. The antiandrogen withdrawal syndrome in relapsed prostate cancer.
Scher HI; Kolvenbag GJ
Eur Urol; 1997; 31 Suppl 2():3-7; discussion 24-7. PubMed ID: 9074903
[TBL] [Abstract][Full Text] [Related]
18. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
[TBL] [Abstract][Full Text] [Related]
19. [Anti-androgen withdrawal syndrome].
Breul J; Paul R
Urologe A; 1998 Mar; 37(2):156-8. PubMed ID: 9563126
[TBL] [Abstract][Full Text] [Related]
20. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
Kelly WK; Slovin S; Scher HI
Urol Clin North Am; 1997 May; 24(2):421-31. PubMed ID: 9126240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
